论文部分内容阅读
目的观察吉西他滨和多西紫杉醇单药治疗高龄晚期非小细胞肺癌的疗效、消化道反应、骨髓抑制情况,进行对比研究,以探讨高龄晚期非小细胞肺癌的有效、安全的治疗方案。方法吉西他滨组32例,采用吉西他滨单药化疗,剂量为1250mg/m2,静脉滴注,第1、8天用药,每21天为1周期,至少4周期。多西紫杉醇组35例,多西紫杉醇35mg/m2静脉滴注,d1,8天用药,每21天为1周期,至少4周期。对照组41例,进行最佳支持治疗(best support cure)。治疗2周期后进行胸部CT扫描以评价疗效,疗效及毒性反应按WHO标准进行评价。结果吉西他滨、多西紫杉醇、对照组总有效率分别为28.1%,31.4%,0%,多西紫杉醇组和吉西他滨组疗效均高于对照组,吉西他滨单药治疗高龄晚期非小细胞肺癌是有效率和多西紫杉醇相近。吉西他滨毒性主要表现为血小板降低,而多西紫杉醇主要表现为白细胞减少,但未出现出血性危险和严重感染病例,两者在单药治疗高龄非小细胞肺癌中都是安全有效的。
Objective To observe the curative effect, digestive tract reaction and myelosuppression of gemcitabine and docetaxel in the treatment of advanced non-small cell lung cancer (NSCLC), and to compare the efficacy and safety of gemcitabine and docetaxel in the treatment of advanced non-small cell lung cancer. Methods Gemcitabine group, 32 cases, with gemcitabine single-agent chemotherapy, a dose of 1250mg / m2, intravenous drip, the first and eighth days of medication, every 21 days for a period of at least 4 cycles. Docetaxel group 35 cases, docetaxel 35mg / m2 intravenous drip, d1, 8 days medication, every 21 days for a period of at least 4 cycles. Control group, 41 cases, the best support cure (best support cure). After 2 cycles of treatment, chest CT scan was performed to evaluate the curative effect, curative effect and toxicity response according to WHO standard. Results The total effective rates of gemcitabine, docetaxel and control group were 28.1%, 31.4% and 0%, respectively. The efficacy of docetaxel group and gemcitabine group were higher than that of the control group. Gemcitabine monotherapy was effective for advanced advanced non-small cell lung cancer Similar to docetaxel. Gemcitabine toxicity is mainly manifested as thrombocytopenia, and docetaxel is mainly manifested as leukopenia, but no hemorrhagic risk and serious infections, both of which are safe and effective in the treatment of advanced non-small cell lung cancer.